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690Characteristics of CliniMACS System CD34-Enriched
T Cell-Depleted Grafts in a Multicenter Trial for Acute
Myeloid Leukemia-Blood and Marrow Transplant
Clinical Trials Network (BMT CTN) Protocol 0303
Carolyn A. Keever-Taylor,1 Steven M. Devine,2 Robert J. Soiffer,3 Adam Mendizabal,4
Shelly Carter,4 Marcelo C. Pasquini,1 Parameswaran N. Hari,1 Anthony Stein,5
Hillard M. Lazarus,6 Charles Linker,7 Steven C. Goldstein,8
Edward A. Stadtmauer,8 Richard J. O’Reilly9Eight centers participated in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol
0303 to determine the effect of extensive T cell depletion (TCD) on the outcome of HLA matched sibling
donor transplantation for acute myeloid leukemia. One goal of the study was to determine if TCD could be
performed uniformly among study sites. TCDwas achieved using the CliniMACSCD34 Reagent System for
CD34 enrichment. Processed grafts needed to contain$2.0 106 CD341cells/kg with a target of 5.0 106
CD341 cells/kg and\105 CD31 T cells/kg. Up to 3 collections were allowed to achieve the minimum
CD341 cell dose. In total, 86 products were processed for 44 patients. Differences in the starting cell prod-
ucts between centers were seen in regard to total nucleated cells, CD341 cells, and CD31 T cells, which
could in part be ascribed to a higher dose of granulocyte-colony stimulating factor used for mobilization early
in the trial. Differences between centers in processing outcomes were minimal and could be ascribed to
starting cell parameters or to differences in graft analysis methods. Multivariate analysis showed that
CD341 cell recovery (66.1% 6 20.3%) was inversely associated with the starting number of CD341 cells
(P5.02). Median purity of the CD34 enriched fraction was 96.7% (61.5%-99.8%) with monocytes and B cells
the most common impurity. All patients received the minimumCD341 cell dose, and 39 patients (89%) came
within 10% or exceeded the target CD341 cell dosewithout exceeding the maximumT cell dose. All patients
proceeded to transplantation and all achieved initial engraftment. Products processed at multiple centers us-
ing the CliniMACS System for CD34 enrichment were comparably and uniformly highly enriched for CD341
cells, with good CD341 cell recovery and very low CD31 T cell content.
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A number of single andmulticenter trials have dem-
onstrated favorable outcomes with the use of ex vivo
T cell depletion (TCD) for acute myeloid leukemia
patients in complete remission undergoing hematopoi-
etic progenitor cell transplantation (HPCT) [1-6].
These studies have shown a high rate of engraftment,
minimal transplant-related complications, and, in con-
trast to recipients of T cell–depleted grafts with chronic
myelogenous leukemia, relapse rates that do not exceed
that of recipients of non-TCD grafts. However, these
studies have differed significantly both in the criteria
for patient selection as well as the method and degree
of TCD.
The Blood andMarrow Transplant Clinical Trials
Network (BMT CTN) undertook the BMT CTN
Biol Blood Marrow Transplant 18:690-697, 2012 691Multicenter Processing for CD34 Enrichment0303 trial, designed with defined patient selection
criteria, common protocols for donor mobilization,
and a common preparative regimen [7]. Further, the
trial would use a single method of TCD utilizing the
CliniMACS CD34 Reagent System that would
reduce T cells to the level that no post-HPCT phar-
macological graft-versus-host disease (GVHD) pro-
phylaxis was required. The CliniMACS System has
been in clinical use in Europe since 1998, where it
has consistently produced products that are highly
depleted of CD31 T cells with good recovery of
CD341 cells [8-10]. However, prior studies were
conducted at a limited number of specialized centers.
Therefore, 1 of the objectives of BMT CTN 0303
was to evaluate the consistency of graft processing
outcomes at multiple sites across the network, and to
identify variables in trial design that might improve
consistency for future studies.
Herein we report the characteristics of the prod-
ucts that were processed for patients enrolled in
BMT CTN 0303, the composition of the grafts that
were infused, and the consistency of processing among
centers.MATERIALS AND METHODS
Control of Processing Variables
The CliniMACSCD34 Reagent System, consist-
ing of the CliniMACSplus Instrument, CliniMACS
CD341Reagent, CliniMACS PBS/EDTA buffer, and
CliniMACSTubing Sets, was used for CD341 cell en-
richment. All except 1 of the study-site laboratories
had previous training and experience using the Clini-
MACS system before the trial started. The center
without previous experience underwent training by
Miltenyi technical specialists before enrolling patients.
Before initiation of the clinical trial, representatives
from each of the processing laboratories identified
critical steps in the processing procedure that should
be harmonized to reduce variables that might affect
processing outcome. It was agreed that procedures de-
scribed in the CliniMACS Users’ Manual were to be
strictly followed for the steps performed on the Clini-
MACS System. Hematopoietic progenitor cell apher-
esis products could be held overnight for processing
provided that the cells were diluted to#2.0 108/mL
using concurrent donor plasma or CliniMACS
Buffer as the diluent and were stored in a controlled
environment at 1C to 8C. Products were to be al-
lowed to warm to room temperature before process-
ing. Platelet and antibody wash steps could be
performed using a bag method as described in the
CliniMACS Manual or by using a Cobe 2991 cell
washer (CaridianBCT, Lakewood, CO) as validated
by the laboratories. Because of the limits recommen-
ded by the manufacturer, products that exceeded thelimit of 1.2  1011 total nucleated cell (TNC) of the
CliniMACS Large-Scale Tubing Set needed to be split
and selected on 2 (or more) Tubing Sets. For products
with fewer cells, the regular scale set could be used
with an upper limit of 6.0  1010 cells. Upper limits
of 1.2  109 and 6.0  108 CD341 cells were allowed
for the large-scale tubing and 2 bottles of CD34 Re-
agent, and regular tubing sets with 1 bottle of CD34
Reagent, respectively. All products were to be infused
on the day they were processed after release test results
were known. Products were to be assessed by flow cy-
tometry for CD31 and CD341 cellular content before
processing and for CD341 cell content after antibody
wash, before application to the tubing set. After CD34
enrichment, products were again assessed for cells ex-
pressing CD3 and CD34 in addition to CD56, CD19,
or CD20 and CD14 to further characterize the infused
product. All flow panels were to include the viability
dye, 7-amino-actinomycin-D (7-AAD) to assess over-
all viability and to perform analysis only on viable cells.
TNC together with flow analysis was to be used to
determine absolute viable subset values (dual platform
method) in the final CD34-enriched fraction.
The protocol allowed for split products to be
pooled for final product analysis and release testing.
Products that contained low cell numbers could be
held overnight and pooled with the following day’s
collection for processing. In such cases, flow analysis
was to be performed on the pooled product before
and after processing.
Patients and Donors
A total of 47 patients were enrolled at 8 centers
between October 2005 and December 2008. Three
patients did not proceed to transplantation or product
collection because of withdrawal of informed consent
(n 5 2) or disease progression (n 5 1) and are not in-
cluded in this paper. A full description of patient char-
acteristics for this study, the cytoreduction regimen
employed, and the protocol used to mobilize donor
progenitor cells has been described [7]. The goal was
to infuse a target dose of 5.0 106 CD341 cells/kg pa-
tient body weight containing not more than 1.0  105
CD31 T cells/kg for each patient. Two apheresis
products could be collected to achieve the target
CD341 cell dose, but up to 3 were allowed to reach
the minimum dose of 2.0  106 CD341 cells/kg
without exceeding the CD31 T cell dose. A total of
86 apheresis collections were obtained and processed
for the 44 patients who underwent transplantation.
Statistical Analysis
Descriptive statistics (mean, standard deviation,
median, minimum, maximum, and number) for the pa-
rameters that were analyzed were performed on all
products that were processed for CD34 enrichment.
692 Biol Blood Marrow Transplant 18:690-697, 2012C. A. Keever-Taylor et al.These included products obtained for 4 patients for
whom 3 products were processed, 34 patients for
whom 2 products were processed, and 6 patients for
whom 1 product was processed. In 2 cases, 2 products
were combined for processing on a single tubing set,
and these were counted as 1 procedure reducing the to-
tal number of processing procedures that were ana-
lyzed to 84. Processing outcome was assessed by
evaluating the recovery of CD341 cells from the start-
ing product, the log reduction inCD31Tcells, and the
purity of the CD34-enriched fraction, in addition to
the effect of the processing procedure on cell viability.
The evaluation of factors correlated with CD341
cell recovery and log TCD considered the TNC pro-
cessed for both outcomes, starting absolute CD341
cells for CD341 cell recovery, and starting absolute
CD31 T cells for log TCD. This analysis included
the clinical center as a covariate. Analysis did not in-
clude 4 products that were split for selection because
the CD34-enriched products were pooled before
flow analysis and equal numbers of cells were not
loaded onto the 2 tubing sets used for selection.
Data from 4 centers (centers 5, 6, 7, and 8) per-
forming #4 procedures were pooled for comparison
with centers performing .4 procedures (range: 9-34
procedures) when analyzing starting and ending prod-
uct cell numbers and in comparing center outcomes
for CD341 cell recovery, CD341 cell purity, log
CD31 T cell depletion, and ending product viability.
A linear mixed effect model was used to account for
the repeated measures ($2 procedures for mostCtr 1 Ctr 2 Ctr 3 Ctr 4 Ctrs 5-8
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Figure 1. Starting product characteristics by center. Cellular content of the in
ticipating center. (A) Starting TNC. (B) Starting absolute CD341 cells. (C) Start
bars represent the median for each center. The half open–half closed symbols
Only significant differences between centers are shown. The overall P value fopatients). An overall P value of\.05 indicated mini-
mally 1 center differed from 1 other center in regard
to the product characteristic tested. Pairwise compar-
ison was then performed with Tukey-Kramer adjust-
ment for multiple comparisons.RESULTS
Starting Product Parameters
Individual centers were compared to determine if
there were significant differences in the starting apher-
esis products that might have affected processing out-
comes (Figure 1). Starting TNC was found to be
significantly lower for center 4 compared with center
2 and centers 5 to 8 (Figure 1A). Three of the 5 donors
processed at center 2 underwent graft mobilization us-
ing 16 mg/kg/day of granulocyte-colony stimulating
factor (G-CSF) rather than the 10 mg/kg/day that
was later adopted. Alongwith the higher TNC for cen-
ter 2, the products from this center also contained sig-
nificantly more CD341 cells than centers 1 or 3 and
more CD31 T cells than center 1 (Figure 1B and C).
The lower starting viabilities of the products from cen-
ter 4 differed from all the other centers except center 2.
Overall, the starting products contained 0.84% 6
0.43% CD341 cells and 27.2% 6 12.2% CD31 cells.
Four products, 2 each from center 1 and center 2,
were split for selection on 2 separate tubing sets and
are indicated in Figure 1 by the half-shaded symbols.
In 2 cases, products were pooled for selection onCtr 1 Ctr 2 Ctr 3 Ctr 4 Ctrs 5-8
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dividual apheresis products undergoing CD34 enrichment for each par-
ing absolute CD31 T cells. (D) % viable cells as measured by 7-AAD. The
represent products that were subsequently split for CD34 enrichment.
r the comparison is shown in the lower right of each panel.
0 2 4 6 60 80 100
%TNC Wash Rec
%CD34 Wash Rec
%CD34-Enr Rec
%CD34 Purity
Log TCD
 P=0.04  
Cobe 2991
Bag
Figure 2. Effect of wash method before and after CD34 enrichment.
Data are from 27 products processed by 3 centers using a Cobe 2991
cell washer for the platelet and antibody wash steps and 57 products
processed by 5 centers using a bag method. Results were compared
for the effect of the wash method on TNC and CD341 cell recovery be-
fore addition onto the tubing set, and for CD341 cell recovery and pu-
rity postenrichment, as well as for log TCD. The only significant
difference based on wash method was a higher CD341 cell recovery af-
ter CD34 enrichment. Data are the mean 6 SEM of the 2 groups with
the bag method represented by the white bars and the Cobe 2991
method by the black bars.
Table 1. Overall Outcomes of CD34 Enrichment Procedures
n 5 84 % CD34 Recovery % CD34 Purity Log TCD % Viability
Mean 66.1 93.0 4.8 96.6
SD ±20.3 ±8.3 ±0.6 ±3.8
Median 65.0 96.7 4.9 97.7
Min 29.9 61.5 3.2 74.0
Max 125.6 99.8 5.9 100.0
CD34+ cell recovery and log TCD are calculated based on the starting
apheresis product and the product as recovered from the tubing set.
Viability was assessed by 7-AAD staining.
Biol Blood Marrow Transplant 18:690-697, 2012 693Multicenter Processing for CD34 Enrichmenta single tubing set, although in 1 of the 2 cases pooling
resulted in more than the recommended number of
cells being applied to the column within the tubing set.
Effect of Platelet and Antibody Wash and Wash
Method on TNC and CD341 Cell Content
Samples were obtained from products just before
loading the cells onto the tubing set to determine the
effect of the wash steps required for platelet reduction
and removal of unbound magnetic reagent on TNC
and CD341 cell content. Centers 1, 2, and 6 used the
Cobe 2991 cell washer, whereas the other centers
used blood transfer bags and a centrifuge (bag method)
for the wash steps. Data from center 2 were available
after the platelet wash, indicating that 65.4%6 18.7%
(n5 10) of platelets are removed using the Cobe 2991
method. No significant difference was seen in post-
wash TNC recovery between the Cobe and bag
methods (91.2% 6 10.6% versus 88.0% 6 8.2%, re-
spectively, P 5 .09) or postwash CD341 cell recovery
(95.6%6 23.4% versus 93.8%6 16.8%, respectively,
P 5 .43) (Figure 2, lower bars).
Outcome of Processing for CD341 Cell
Enrichment
CD341 cell recovery postenrichment averaged
66.1% 6 20.3%. The CD34-enriched fraction con-
tained an average of 93.0% CD341 cells and 0.23%
CD31 T cells, representing a 4.8 6 0.6 log reduction
of starting CD31 T cells. Ending cell viability aver-
aged 96.6% (Table 1).
Of all the outcomes, the most significant differ-
ences were seen for CD341 cell recovery withthe highest recoveries seen for centers 1 and 3
(Figure 3A). A significant difference in CD341 cell
purity was only seen between center 1, which had
uniformly very high purities, and the combined centers
5 to 8where there weremore products with a lower pu-
rity (Figure 3B). Only centers 3 and 4 differed from
each other in log TCD (Figure 3C). Center 3 reported
the highest average final product viability that differed
significantly from that reported by centers 1 and 4. All
viabilities were well above the 70% limit for infusion
ranging from 74% to 100% (Figure 3D).
We additionally assessed if the wash method be-
fore CD34 enrichment affected final product CD341
cell purity, CD341 cell recovery, or log TCD. The
only significant difference between the 2 methods
was for CD341 cell yield, which was higher for prod-
ucts washed using the Cobe 2991: 72.6%6 22.5% re-
covery using the Cobe 2991 compared with 63.0% 6
18.5% recovery for bag-washed products (P 5 .044)
(Figure 2, upper bars).Evaluation of Starting Product Factors
Correlating with CD341 Cell Recovery and/or
Log TCD
For the data analysis of the effect of starting cell
numbers on final product outcome, we used the num-
ber of cells that started processing, rather than the
number of cells from the precolumn assessments be-
cause the effect of cell numbers would include the la-
beling of the cells with the CD34 reagent. Four (5%)
of the products analyzed exceeded the recommended
upper TNC limit for 1 or 2 CD34 Reagent vials. How-
ever, only 1 of these 4 products was more than 10%
over the limit.
Seven products (8.8%) (6 requiring 2 reagent vials)
were over the specified upper limit for CD341 cells
with 3 of these .10% over the limit. Neither of the
2 patients for whom products were pooled exceeded
the limit of CD341 cells.
CD341 cell recovery was significantly inversely
correlated with starting numbers of CD341 cells but
not with starting TNC. In contrast, log TCD was in-
versely correlated with starting TNC, although the
correlation was not significant (P 5 .06) and log
TCD was higher with greater numbers of starting
CD31 T cells (P 5 .05) (Table 2).
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Figure 3. Postprocessing outcomes by center. Outcome after CD34-enrichment. (A) Recovery of CD341 cells from starting product. (B) % of the
CD34-enriched fraction that are CD341. (C) Log depletion from starting CD31 T cells. (D) 7-AAD viability of the CD34 enriched fraction. The
bars represent the median for each center. The half open–half closed symbols represent products that were subsequently split for CD34 enrichment.
Only significant differences between centers are shown. The overall P value for the comparison is shown in the lower right of each panel.
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CD34-enriched products contained a median of
96.7% CD341 cells (61.5%-99.8%). Monocytes
were the most common cellular subset other than
CD341 cells, but with a median content of only
0.5% (0%-22.5%). B cells represented the second
most common nontarget cell type with a median of
0.30% (0.0%-7.4%) of the final fraction. Natural killer
cells represented 0.05% (0%-21.3%) of cells within
the CD34-enriched fraction. The most infrequent
cell subset was CD31 T cells representing a median
of 0.07% (0%-2.6%) of the final fractions (Figure 4).
Cell Infusion Doses
For the study overall, 39 (88.6%) of patients re-
ceived within 10% of the target CD341 cell dose of
5.0  106 CD341 cells/kg. Of these, 19 (43.2%) re-
quired a single product, 18 (40.9%) required 2 prod-
ucts, and 2 patients (4.5%) required 3 collections to
reach this dose. Each of the 5 patients whose products
did not contain minimally 90% of the target dose of
CD341 cells exceeded the minimum CD341 cellTable 2. Predictors of CD34+ Cell Recovery and Log TCD
Outcome Predictor
CD34+ cell recovery Starting product TNC
CD34+ cell recovery Starting product CD34+ cell count
Log10 T cell depletion Starting product TNC
Log10 T cell depletion Starting product CD3+ cell count
Variables likely to affect the indicated outcome of products undergoing CD34 e
repeated measurements. The clinical center was included in the model as a codose of 2.0 106 CD341 cells/kg specified by the pro-
tocol. Overall, patients received a mean of 8.8 1066
5.2  106 CD341 cells/kg, ranging from 2.4 to 30.3 
106/kg. Given the high doses of CD341 cells infused,
no significant correlation could be seen between the
dose of CD341 cells infused and time to engraftment
of neutrophils (data not shown). In no case did
the CD31 T cell dose exceed the upper limit of
105/kg. Patients received a mean of 1.5  104 6
2.0  104 CD31 cells/kg, ranging from 0.1 to 8.3 
104. T cell dose did not correlate with the probability
of developing acute GVHD (aGVHD) (data not
shown).DISCUSSION
The BMT CTN trial BMT CTN0303 was de-
signed to minimize intercenter variability of factors
that might affect the outcome of recipients of T cell–
depleted HPC, apheresis grafts mobilized from HLA
identical donors. Other goals were to test a TCD pro-
cessing method sufficiently rigorous to eliminate theCoefficient Estimate of Predictor P Value
0.077 .93
20.002 .02
20.047 .06
0.016 .05
nrichment were assessed using a linear mixed effect model to adjust for
variate.
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Figure 4. Other cellular subsets found in the CD34 enriched products.
CD34-enriched fractions were assessed for other unwanted subsets
including: CD31 T cells (median 5 0.07%, range: 0.0%-2.6%, n 5 84),
CD19 or CD201 B cells (median 5 0.28%, range: 0.0%-7.4%, n 5 79),
CD561 natural killer cells (median 5 0.05%, range: 0.0%-21.3%, n 5 69),
and CD141 monocytes (median 5 0.5%, range: 0.0%-22.5%, n 5 65).
The horizontal bar represents the median.
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prevent clinically severe GVHD while allowing for
the infusion of large numbers of CD341 cells to pro-
mote rapid engraftment. These goals were achieved
in that in the absence of posttransplantation GVHD
prophylaxis patients onBMTCTN0303had a cumula-
tive incidence of aGVHD grades 2-4 of 22.7% with
only 7.6% experiencing extensive chronic GVHD at
2 years, and all patients engrafted neutrophils and
platelets at a median of 12 days (range: 9-19 days)
and 16 days (range: 13-159), respectively [7].
The CliniMACS CD34 Reagent System for CD34
enrichment has been shown to be highly effective in re-
ducing T cell content such that GVHD incidence is
extremely low even in the setting of HLA disparity
[1,2]. The success of this device in producing graft
products that have a very low T cell content and
good recovery of CD341 cells from the starting
apheresis product has been demonstrated in multiple
single-center studies [11-13]. However, to date, there
have been few published studies involving multiple
institutions that demonstrate that this method for
TCD is exportable and reproducible. We demon-
strated that the results of 84 products processed in 8
different centers over the course of the BMT CTN
0303 clinical trial were consistent and that additional
processing steps to further standardize the procedure
were not necessary.
Differences in the starting products were seen for
TNC CD341 cell content and viability. Significantly
higher numbers of starting cells were mostly limitedto a single center (center 2) wheremore of the products
were collected early in the study from donors given
G-CSF at 16 mg/kg/day as the mobilization stimulus.
In part, because of the high cellular content of these
first products, changes were made in the protocol
to reduce the G-CSF dose to 10 mg/kg/day. The 7-
AAD viability of the starting product was significantly
lower for center 4 compared with most of the other
centers, most likely because of this center’s use of
a flow cytometry staining method that did not utilize
washes after antibody or lysing reagent additions as
opposed to the other laboratories where wash steps
that likely removed a portion of the dead cells were
used.
The use of a cell washermethod or a bagmethod to
remove unwanted platelets and unbound magnetic
bead reagent that might interfere with the selection
process was an acceptable variation in the processing
used by 3 of the 8 centers, We confirmed that there
was no statistical difference in the recovery of TNC
or CD341 cells immediately after the wash steps, nor
were differences seen in log TCD or CD341 cell pu-
rity post-CD34 enrichment. However, there was im-
proved recovery of CD341 cells in centers using the
cell washer. Previously published data using the Clin-
iMACSCD34 Reagent System have shown a better re-
covery and purity of CD34-enriched products using
a system that results in 95% to 99% of platelets being
removed compared with the 25% to 40% removal
achieved using the bag method described in the Clin-
iMACS Users’ Manual [13,14]. Platelets are thought
to decrease CD341 cell recovery by interfering with
the binding of the immunomagnetic reagent to the
CD341 cells. Data from 1 of the 3 centers using the
Cobe 2991 for the platelet wash step indicated that
approximately 65% of the platelets are removed
using this method, which may be sufficient for the
improved CD341 cell recovery that was observed.
The final CD34-enriched product is the best mea-
sure of processing consistency between centers. Signif-
icant differences between centers in CD34 recovery
mostly involved center 1 where in 4 cases recovery ex-
ceeding 100%was reported. Careful review of the data
did not reveal any errors in data recording or reporting
to explain the results for those products. The compara-
bility of the assessment of CD341 cell content by flow
in apheresis products between centers has been the
subject of multiple studies, most of which found signif-
icant differences between laboratories in how the flow
testing and analysis was performed [15-17]. The BMT
CTN 0303 trial required that participating flow
cytometry laboratories use a validated assay, be
accredited by the College of American Pathologists,
and participate in graded CD34 proficiency studies.
However, a standard method for performing the
flow assay was not mandated. Analysis of the final
CD34-enriched product for CD341 cell content
696 Biol Blood Marrow Transplant 18:690-697, 2012C. A. Keever-Taylor et al.does not suffer from the same technical difficulties as-
sociated with the starting product, namely, issues of
rare event analysis. Therefore, it seems likely the post-
processing assessment is the more accurate number,
and the starting CD341 cell content may have been
underestimated in cases where CD341 cell recovery
is .100%. Variation in cell counting methods may
have also contributed because a 2-platform method
for determining the absolute number of CD341 cells
was used by all centers for the final fraction, whereas
the centers were divided in using a single- versus
a dual-platform method for the starting absolute
CD341 cell numbers.
CD341 cell purity and log TCD were more con-
sistent between the centers, although there was
a higher purity of products produced by center 1 com-
pared with the pooled results from centers 5 to 8. After
CD341 cells, monocytes were the highest frequency
cell type, with 1 product containing 22% CD141
monocytes and a second product with 8.7% mono-
cytes. B cells were the second most frequent contami-
nant. It is likely that both monocytes and B cells may
be nonspecifically captured during enrichment by
binding of the antibody conjugated directly onto the
magnetic beads through Fc receptors. Only center 3
and center 4 differed from one another in regard to
log TCD for reasons that have not been identified.
Center 3 reported final product viability that was
very close to 100% for all products, causing this center
to differ significantly from center 1 and center 4 for
this variable.
The association between poorer CD341 cell re-
covery and the higher number of CD341 cells loaded
onto the column/tubing set revealed in the multivari-
ate analysis was the major difference between centers
that might be ascribed to the CliniMACS CD34
Reagent System. The CliniMACS Users’ Manual rec-
ommends limiting the number of CD341 cells that
should be treated with the CliniMACS CD34 Reagent
and the number that should be loaded onto a single
tubing set. Seven of the products evaluated for factors
affecting CD341 cell recovery exceeded the recom-
mended loading dose of CD341 cells, 3 of which
were more than 10% above this limit. Two of the 3
products that exceeded the loading limit by more
than 10% had\50% recovery, indicating that this up-
per limit for CD341 cells should not be exceeded. Our
observations are in agreement with a recently pub-
lished analysis of a large number of products processed
at multiple centers showing that TNC in excess of that
recommended by the manufacturer does not affect
device performance, whereas exceeding the re-
commended CD341 cell limit reduces CD341 cell
recovery [10].
Even though differences among centers were seen
in the statistical analysis, all centers were able to pro-
cess final graft products that easily met the criteria ofthe study. The center differences in the processing
outcomes mostly could be explained by differences in
the flow cytometry methods that were used. Future tri-
als may benefit from a higher degree of standardization
of flow methods as well as requiring that the upper
loading limit of CD341 cells be strictly observed.
We conclude that the use of the Miltenyi CliniMACS
CD34Reagent System forTCD in the setting of amul-
ticenter trial results in products that are sufficiently
uniform in regard to CD341 cell content and contain
very low numbers of CD31 T cells.ACKNOWLEDGMENTS
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